Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

Question 2

How does Garsorasib compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial fit into my overall treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC clinical trial (NCT07294261). Contact the study team or your healthcare provider for specific answers.

What this study is about